Retrospective Analysis of Locally Advanced Noninflammatory Breast Cancer From Chennai, South India, 1990–1999

Shanta, V.; Swaminathan, Rajaraman; Ranganathan, Rama; Radhika, R

doi:10.1016/j.ijrobp.2007.05.050

Cited by 43 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To our knowledge, this is the first prospective study that reports an association of pathologic response with survival after primary concurrent chemoradiation. The results reported are comparable to those from a large retrospective cohort of 1,117 LABC patients treated with concurrent chemoradiation in South India: pathologic response occurred in 33% of patients and was associated with improved DFS, consistent with our findings [42]. …”

Section: Discussionsupporting

confidence: 91%

Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival

Adams

Chakravarthy

Donach

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

We have previously demonstrated high pathologic response rates after neoadjuvant concurrent chemoradiation in patients with locally advanced breast cancer (LABC). We now report disease-free survival (DFS) and overall survival (OS) in the context of pathologic response. 105 LABC patients (White 46%, Non-White 54%) were treated with paclitaxel (30 mg/m2 intravenously twice a week) for 10–12 weeks. Daily radiotherapy was delivered to breast, axillary, and supraclavicular lymph nodes during weeks 2–7 of paclitaxel treatment, at 1.8 Gy per fraction to a total dose of 45 Gy with a tumor boost of 14 Gy at 2 Gy/fraction. Pathological complete response (pCR) was defined as the absence of invasive cancer in breast and lymph nodes and pathological partial response (pPR) as the persistence of <10 microscopic foci of invasive carcinoma in breast or lymph nodes. Pathologic response (pCR and pPR) after neoadjuvant chemoradiation was achieved in 36/105 patients (34%) and was associated with significantly better DFS and OS. Pathological responders had a lower risk of recurrence or death (HR = 0.35, P = 0.01) and a longer OS (HR = 4.27, P = 0.01) compared with non-responders. Median DFS and OS were 57 and 84 months for non-responders, respectively, and have not yet been reached for responders. Importantly, pathologic response was achieved in 54% of patients with HR negative tumors (26/48). In conclusion, pathologic response to concurrent paclitaxel-radiation translated into superior DFS and OS. Half of the patients with HR negative tumors achieved a pathologic response.

show abstract

Section: Discussionsupporting

confidence: 91%

Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival

Adams

Chakravarthy

Donach

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…[9] All patients received hormonal therapy irrespective of the receptor status. Ovarian ablation was offered to all the patients.…”

Section: Methodsmentioning

confidence: 99%

Quality of life among young women with breast cancer: Study from a tertiary cancer institute in south India

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Shanta et al [29] reported a similar nodal downstaging in 57% of 1,117 consecutive cases of LABC. Patients with pN0 had a 50% better prognosis compared to patients with N+, irrespective of primary tumor sterility.…”

Section: Nodal Remission Ratesmentioning

confidence: 82%

“…Patients with pN0 had a 50% better prognosis compared to patients with N+, irrespective of primary tumor sterility. Shanta et al [29] as well as Lerouge et al [21] proved, that patients with nodal downstaging from cN+ to pN0 had the same good prognosis as patients, who presented with cN0 and had pN0 at axillary dissection.…”

Section: Nodal Remission Ratesmentioning

confidence: 94%

See 1 more Smart Citation

Retrospective Study of Neoadjuvant Versus Adjuvant Radiochemotherapy in Locally Advanced Noninflammatory Breast Cancer

et al. 2010

View full text Add to dashboard Cite

Purpose: This retrospective study compares patients treated between 1991 and 1998 with neoadjuvant radiotherapy ± chemotherapy (RCT) or adjuvant RCT for locally advanced noninflammatory breast cancers (LABC) in terms of pathologic complete response (pCR), 10-year relapse-free (RFS), and overall survival (OS). Patients and Methods: Preoperative RCT in 315 and adjuvant RCT in 329 cases consisted in 50 Gy (5 × 2 Gy/week) to the breast and the supra-/infraclavicular lymph nodes. 101 neoadjuvant patients received -in case of breast conservation -a 10-Gy interstitial boost with 192 Ir afterloading before and 214 neoadjuvant patients a preoperative electron boost after external-beam radiotherapy. In the neoadjuvant RCT group, chemotherapy was applied prior to radiotherapy in 192 patients, and simultaneously in 113; ten had no chemotherapy. In the adjuvant RCT group, chemotherapy was applied to 44 patients before surgery and to 166 after surgery; 119 had no chemotherapy. Results: Breast conservation became possible in 50.8% after neoadjuvant RCT for LABC with a pCR rate at surgery of 29.2%. A complete nodal remission (pN0) after RCT was observed in 56% (89/

show abstract

Retrospective Analysis of Locally Advanced Noninflammatory Breast Cancer From Chennai, South India, 1990–1999

Cited by 43 publications

References 23 publications

Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival

Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival

Quality of life among young women with breast cancer: Study from a tertiary cancer institute in south India

Retrospective Study of Neoadjuvant Versus Adjuvant Radiochemotherapy in Locally Advanced Noninflammatory Breast Cancer

Contact Info

Product

Resources

About